MGNX

The investors in MacroGenics, Inc.'s (NASDAQ:MGNX) will be rubbing their hands together with glee today, after the share price leapt 41% to US$4.16 in the week following its quarterly results. Revenues were 36% better than analyst models forecast, at US$21m. Perhaps unsurprisingly, statutory losses were also slightly larger than expected, at US$0.58 per share, reflecting the higher costs which were likely incurred in generating that revenue. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Following the recent earnings report, the consensus from six analysts covering MacroGenics is for revenues of US$109.8m in 2026. This implies a substantial 30% decline in revenue compared to the last 12 months. Losses are forecast to balloon 52% to US$1.68 per share. Before this latest report, the consensus had been expecting revenues of US$106.9m and US$1.47 per share in losses. While this year's revenue estimates increased, there was also a notable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock. See our latest analysis for MacroGenics It will come as a surprise to learn that the consensus price target rose 13% to US$6.75, with the analysts clearly more interested in growing revenue, even as losses intensify. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values MacroGenics at US$9.00 per share, while the most bearish prices it at US$4.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. One way to get more context on these forecasts is to look at how they compare to both past...

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 million in combined proceeds ADC pipeline remains on track for multiple data disclosures and program milestones Cash runway guidance extended through 2028, based on anticipated closing of manufacturing divestiture ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress. “We are very pleased to report a strong start to the year, building on the momentum generated in 2025. These results reflect our team’s disciplined execution of a strategy designed to sharpen our focus, maximize the value of our pipeline, and strengthen our financial position. As part of this effort, we recently announced the sale of our GMP manufacturing operations to Bora Pharmaceuticals and the monetization of additional ZYNYZ royalties with Sagard Healthcare Partners. Subject to the closing of the manufacturing operations divestiture, these transactions are expected to provide significant non-dilutive capital to support growth opportunities in 2026 and beyond,” said Eric Risser, President and CEO of MacroGenics. “We look forward to providing multiple updates during the remainder of the year, including key programmatic milestones for MGC026, MGC028, and MGC030. We believe our increased focus on discovering and developing breakthrough medicines has the potential to enhance patients’ lives while creating meaningful value for our shareholders.” Focus and Realignment Across Our Business MacroGenics recently took a series of significant steps designed to focus resources on the Company’s innovative oncology programs. These steps include: Divestiture of Manufacturing Operations. As announced earlier this week, MacroGenics entered into a definitive agreement with Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora) to sell its manufacturing operations, inclusive of drug substance manufacturing, development and quality services. Subject to customary closing conditions, MacroGenics is ex...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — MacroGenics Inc. (MGNX) on Wednesday reported a loss of $36.8 million in its first quarter. On a per-share basis, the Rockville, Maryland-based company said it had a loss of 58 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share. The biopharmaceutical company posted revenue of $20.8 million in the period, beating Street forecasts. Four analysts surveyed by Zacks expected $18.4 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MGNX at https://www.zacks.com/ap/MGNX

MacroGenics (MGNX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This biopharmaceutical company is expected to post quarterly loss of $0.56 per share in its upcoming report, which represents a year-over-year change of +13.9%. Revenues are expected to be $21.22 million, up 60.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 22.3% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP reading...

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026 Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline. “I am excited about MacroGenics' future prospects, and am inspired by the commitment of our employees over the past few quarters to sharpen our focus and advance our strategic priorities," said Eric Risser, President and CEO of MacroGenics. "Looking ahead, we anticipate several important milestones in 2026, including initial clinical data from the Phase 1 studies of MGC026 and MGC028, and from the LINNET study of lorigerlimab. Additionally, we plan to submit an IND for MGC030, a first-in-class topoisomerase I inhibitor-based ADC. Finally, with cash runway into late 2027, we believe we are well positioned to execute on our plan and drive meaningful value for our shareholders." Corporate Progress and Anticipated Milestones Innovative ADC Pipeline MacroGenics is developing potential best-in-class or first-in-class antibody-drug conjugates (ADCs) that leverage its protein engineering expertise and incorporate potent glycan-linked exatecan payloads designed to enable an expanded therapeutic window. The proprietary drug-linker platform is licensed from Synaffix B.V., a Lonza company. MacroGenics' two clinical-stage ADC programs, MGC026 and MGC028, have demonstrated acceptable safety profiles to date, with no observations of interstitial lung disease, as well as encouraging early evidence of anti-tumor activity by Response Evaluation Criteria in Solid Tumors (RECIST). MGC026 targets B7-H3, an antigen with broad expression across multiple solid tumors and a member of the B7 family of molecules involved in immune regulation. The Company completed enrollment of a Phase...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — MacroGenics Inc. (MGNX) on Monday reported a loss of $14.2 million in its fourth quarter. The Rockville, Maryland-based company said it had a loss of 22 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. The biopharmaceutical company posted revenue of $41.2 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $24.1 million. For the year, the company reported a loss of $74.6 million, or $1.18 per share. Revenue was reported as $149.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MGNX at https://www.zacks.com/ap/MGNX

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +300.00%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of +500%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. BioLife Solutions, which belongs to the Zacks Medical - Products industry, posted revenues of $24.76 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.16%. This compares to year-ago revenues of $22.71 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioLife Solutions shares have lost about 7.1% since the beginning of the year versus the S&P 500's gain of 1.5%. While BioLife Solutions has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioLife Solutions was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete li...

Investors in MacroGenics, Inc. (NASDAQ:MGNX) had a good week, as its shares rose 9.5% to close at US$1.50 following the release of its quarterly results. In addition to smashing expectations with revenues of US$73m, MacroGenics delivered a surprise statutory profit of US$0.27 per share, a notable improvement compared to analyst expectations of a loss. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on MacroGenics after the latest results. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. After the latest results, the consensus from MacroGenics' five analysts is for revenues of US$103.7m in 2026, which would reflect a chunky 19% decline in revenue compared to the last year of performance. Per-share losses are expected to explode, reaching US$1.52 per share. Before this latest report, the consensus had been expecting revenues of US$91.7m and US$1.79 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates. View our latest analysis for MacroGenics Yet despite these upgrades, the analysts cut their price target 19% to US$3.40, implicitly signalling that the ongoing losses are likely to weigh negatively on MacroGenics' valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on MacroGenics, with the most bullish analyst valuing it at US$5.00 and the most bearish at US$2.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that revenue is expected...

MacroGenics (MGNX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of a loss of $0.48 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +156.25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.59 per share when it actually produced a loss of $0.57, delivering a surprise of +3.39%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. MacroGenics, which belongs to the Zacks Medical - Products industry, posted revenues of $72.84 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 157.20%. This compares to year-ago revenues of $110.71 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. MacroGenics shares have lost about 53.2% since the beginning of the year versus the S&P 500's gain of 16.4%. While MacroGenics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for MacroGenics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #...

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancer Cash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided an update on its recent corporate progress. “During the third quarter, our team aggressively advanced each of our previously outlined strategic priorities, which we believe will position MacroGenics for long-term success. Importantly, we secured $75 million in additional non-dilutive partnership payments, which we expect to receive during the fourth quarter. As part of these recent partnering activities, we extended our relationship with Gilead to include a preclinical program based on our novel T-cell engager platform,” said Eric Risser, President and CEO of MacroGenics. “On the clinical front, following a portfolio review and evaluation of interim data from the LORIKEET study, we have decided not to pursue further development of lorigerlimab in prostate cancer. Despite this decision, we remain committed to exploring lorigerlimab’s potential in ovarian and other gynecologic cancers and continue to enroll patients in the Phase 2 LINNET study. We also continue to advance our three other ADC programs and recently initiated two Phase 1 expansion cohorts for the MGC026 program.” “Our team continues to be laser-focused on building shareholder value by advancing treatment options that have transformative potential for patients. We look forward to continuing to deliver on our strategic priorities to position the company for success in 2026 and beyond,” Mr. Risser concluded. Key Strategic Priorities for 2025 and 2026 Determine development path for lorigerlimab. Advance portfolio of antibody-drug conjugates (ADCs), including MGC026, MGC028, and MGC030. Initiate Investigational New Drug (IND)-enabling studies for two new product candidates. Forge partnerships and collaborations to accelerate development of Mac...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — MacroGenics Inc. (MGNX) on Wednesday reported third-quarter earnings of $16.8 million. The Rockville, Maryland-based company said it had net income of 27 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share. The biopharmaceutical company posted revenue of $72.8 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $28.3 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MGNX at https://www.zacks.com/ap/MGNX

Explore MacroGenics's Fair Values from the Community and select yours Revenue: US$22.2m (up 106% from 2Q 2024). Net loss: US$36.3m (loss narrowed by 35% from 2Q 2024). US$0.57 loss per share (improved from US$0.89 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 21%. Looking ahead, revenue is expected to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. Performance of the American Biotechs industry. The company's shares are up 2.6% from a week ago. We don't want to rain on the parade too much, but we did also find 3 warning signs for MacroGenics (1 is significant!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.